Daré Bioscience, Inc. (DARE)

Daré Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	2.81	10	0	0	0
Revenue Growth (YoY)	-71.92%	-	-	-	-
Gross Profit	2.81	10	0	0	0
Selling, General & Admin	12.11	11.24	8.35	6.55	5.27
Research & Development	21.54	30.04	30.62	20.77	8.55
Other Operating Expenses	0.1	0.1	0.1	0.08	0.53
Operating Expenses	33.75	41.39	39.07	27.4	14.34
Operating Income	-30.94	-31.39	-39.07	-27.4	-14.34
Other Expense / Income	-0.78	-0.44	-0.37	-0	-0.08
Pretax Income	-30.16	-30.95	-38.7	-27.4	-14.26
Net Income	-30.16	-30.95	-38.7	-27.4	-14.26
Preferred Dividends	0	0	0	0.01	0.79
Net Income Common	-30.16	-30.95	-38.7	-27.41	-15.05
Shares Outstanding (Basic)	7	7	5	3	1
Shares Outstanding (Diluted)	7	7	5	3	1
Shares Change	3.23%	38.29%	103.23%	93.15%	45.16%
EPS (Basic)	-4.20	-4.44	-7.56	-10.92	-11.64
EPS (Diluted)	-4.20	-4.44	-7.56	-10.92	-11.64
Free Cash Flow	-39.49	-18.15	-28.78	-25.25	-13.32
Free Cash Flow Per Share	-5.43	-2.58	-5.65	-10.07	-10.26
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-1101.89%	-313.85%	-	-	-
Profit Margin	-1074.17%	-309.48%	-	-	-
Free Cash Flow Margin	-1406.26%	-181.51%	-	-	-
EBITDA	-30.07	-30.9	-38.77	-27.52	-14.28
EBITDA Margin	-1070.88%	-309.00%	-	-	-
Depreciation & Amortization	0.09	0.05	-0.07	-0.12	-0.02
EBIT	-30.16	-30.95	-38.7	-27.4	-14.26
EBIT Margin	-1074.17%	-309.48%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).